AI ScreeningAI ChatPricing
  1. US-listed companies
  2. Blueprint Medicines Corp
  3. Financials
  4. Stock-based compensation

Blueprint Medicines Corp【BPMC】

Market cap
$8.4B
P/E ratio
SummaryFinancials
Period EndStock-based compensation (Million USD)YoY (%)
Dec 31, 2024109+17.52%
Dec 31, 202393-6.36%
Dec 31, 202299+8.01%
Dec 31, 202192+21.32%
Dec 31, 202076+38.19%
Dec 31, 201955+78.99%
Dec 31, 201831+143.82%
Dec 31, 201713+103.96%
Dec 31, 20166+18.53%
Dec 31, 20155

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)